Quest Diagnostics Incorporated (DGX)

Market Cap	20.68B +22.2%
Revenue (ttm)	10.85B +13.7%
Net Income	963.00M +15.2%
EPS	8.51 +14.5%
Shares Out	111.24M
PE Ratio	21.83
Forward PE	18.25
Dividend	$3.20 (1.72%)
Ex-Dividend Date	Jan 13, 2026

Volume	36,254
Open	185.34
Previous Close	185.17
Day's Range	185.13 - 186.27
52-Week Range	157.20 - 197.55
Beta	0.68
Analysts	Buy
Price Target	196.69 (+5.8%)
Earnings Date	Feb 10, 2026

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 56,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.

Analyst Summary

According to 13 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $196.69, which is an increase of 5.80% from the latest price.

Price Target

$196.69

(5.80% upside)

Analyst Consensus: Buy